The North America Infertility Drugs Market should witness market growth of 5.6% CAGR during the forecast period (2022-2028).
Medicaid's reimbursement of maternity and family planning services stands in contrast with its complete absence of coverage for fertility treatments. Medicaid supports the bulk of publicly funded family planning services as well as roughly half of the births in the U.S. As a consequence, even though numerous contraceptive and low-income services are often offered throughout pregnancy, there is limited access to help for low-income pregnancies. Only one state, New York, permits Medicaid to pay for fertility services in the United States as of January 2020. These are the main obstacles to market expansion.
Governments have launched a number of programs to help those who are struggling with infertility by offering insurance coverage for therapy. The Ministry of Health, Labor, and Welfare (MHLW), for instance, announced the payment under the national health insurance program in March 2022. By reducing the cost by 70% and increasing the number of prescriptions for medications, this program improves patients' access to care.
It is also anticipated that the availability of a broad range of medications for the treatment of infertility issues would benefit the industry. For instance, some of the fertility drugs on the market include Crinone (progesterone gel), Pregnyl (chorionic gonadotropin), Ovidrel (choriogonadotropin alfa), Menopur (Gonal-F), Follistim A (follitropin beta), Ganirelix Acetate Injection, Cetrotide (cetrorelix acetate), Clomid (clomiphene citrate), Bravelle (urofollitropin), and First-Progesterone.
One of the main factors influencing the development of the infertility medications market in the U.S. is the high concentration of market participants or manufacturer's presence, acquisitions, and partnerships among significant companies and an increase in the number of infertility and PCOS patients in the nation. These occurrences thus show that the market in the United States is expanding significantly. As a result of the aforementioned variables, the North American region expects the studied market to increase.
The US market dominated the North America Infertility Drugs Market by Country in 2021; thereby, achieving a market value of $1, 312.5 million by 2028. The Canada market is experiencing a CAGR of 8% during (2022-2028). Additionally, The Mexico market would exhibit a CAGR of 7% during (2022-2028).
Based on End-user, the market is segmented into Women and Men. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Specialty & Retail Pharmacy, and Online Pharmacy. Based on Drug Class, the market is segmented into Gonadotropins, Aromatase Inhibitors, Selective Estrogen Receptor Modulators (SERMs), Dopamine Agonists, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Bayer AG, Novartis AG, Merck & Co., Inc., Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Sanofi S.A., Ferring Holdings SA, Organon & Co. and Mankind Pharma Ltd.
Medicaid's reimbursement of maternity and family planning services stands in contrast with its complete absence of coverage for fertility treatments. Medicaid supports the bulk of publicly funded family planning services as well as roughly half of the births in the U.S. As a consequence, even though numerous contraceptive and low-income services are often offered throughout pregnancy, there is limited access to help for low-income pregnancies. Only one state, New York, permits Medicaid to pay for fertility services in the United States as of January 2020. These are the main obstacles to market expansion.
Governments have launched a number of programs to help those who are struggling with infertility by offering insurance coverage for therapy. The Ministry of Health, Labor, and Welfare (MHLW), for instance, announced the payment under the national health insurance program in March 2022. By reducing the cost by 70% and increasing the number of prescriptions for medications, this program improves patients' access to care.
It is also anticipated that the availability of a broad range of medications for the treatment of infertility issues would benefit the industry. For instance, some of the fertility drugs on the market include Crinone (progesterone gel), Pregnyl (chorionic gonadotropin), Ovidrel (choriogonadotropin alfa), Menopur (Gonal-F), Follistim A (follitropin beta), Ganirelix Acetate Injection, Cetrotide (cetrorelix acetate), Clomid (clomiphene citrate), Bravelle (urofollitropin), and First-Progesterone.
One of the main factors influencing the development of the infertility medications market in the U.S. is the high concentration of market participants or manufacturer's presence, acquisitions, and partnerships among significant companies and an increase in the number of infertility and PCOS patients in the nation. These occurrences thus show that the market in the United States is expanding significantly. As a result of the aforementioned variables, the North American region expects the studied market to increase.
The US market dominated the North America Infertility Drugs Market by Country in 2021; thereby, achieving a market value of $1, 312.5 million by 2028. The Canada market is experiencing a CAGR of 8% during (2022-2028). Additionally, The Mexico market would exhibit a CAGR of 7% during (2022-2028).
Based on End-user, the market is segmented into Women and Men. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Specialty & Retail Pharmacy, and Online Pharmacy. Based on Drug Class, the market is segmented into Gonadotropins, Aromatase Inhibitors, Selective Estrogen Receptor Modulators (SERMs), Dopamine Agonists, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Bayer AG, Novartis AG, Merck & Co., Inc., Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Sanofi S.A., Ferring Holdings SA, Organon & Co. and Mankind Pharma Ltd.
Scope of the Study
By End-user
- Women
- Men
By Distribution Channel
- Hospital Pharmacy
- Specialty & Retail Pharmacy
- Online Pharmacy
By Drug Class
- Gonadotropins
- Aromatase Inhibitors
- Selective Estrogen Receptor Modulators (SERMs)
- Dopamine Agonists
- Others
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- Bayer AG
- Novartis AG
- Merck & Co., Inc.
- Pfizer, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Sanofi S.A.
- Ferring Holdings SA
- Organon & Co.
- Mankind Pharma Ltd.
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Infertility Drugs Market, by End User
1.4.2 North America Infertility Drugs Market, by Distribution Channel
1.4.3 North America Infertility Drugs Market, by Drug Class
1.4.4 North America Infertility Drugs Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. North America Infertility Drugs Market by End-user
3.1 North America Women Market by Country
3.2 North America Men Market by Country
Chapter 4. North America Infertility Drugs Market by Distribution Channel
4.1 North America Hospital Pharmacy Market by Country
4.2 North America Specialty & Retail Pharmacy Market by Country
4.3 North America Online Pharmacy Market by Country
Chapter 5. North America Infertility Drugs Market by Drug Class
5.1 North America Gonadotropins Market by Country
5.2 North America Aromatase Inhibitors Market by Country
5.3 North America Selective Estrogen Receptor Modulators (SERMs) Market by Country
5.4 North America Dopamine Agonists Market by Country
5.5 North America Others Market by Country
Chapter 6. North America Infertility Drugs Market by Country
6.1 US Infertility Drugs Market
6.1.1 US Infertility Drugs Market by End-user
6.1.2 US Infertility Drugs Market by Distribution Channel
6.1.3 US Infertility Drugs Market by Drug Class
6.2 Canada Infertility Drugs Market
6.2.1 Canada Infertility Drugs Market by End-user
6.2.2 Canada Infertility Drugs Market by Distribution Channel
6.2.3 Canada Infertility Drugs Market by Drug Class
6.3 Mexico Infertility Drugs Market
6.3.1 Mexico Infertility Drugs Market by End-user
6.3.2 Mexico Infertility Drugs Market by Distribution Channel
6.3.3 Mexico Infertility Drugs Market by Drug Class
6.4 Rest of North America Infertility Drugs Market
6.4.1 Rest of North America Infertility Drugs Market by End-user
6.4.2 Rest of North America Infertility Drugs Market by Distribution Channel
6.4.3 Rest of North America Infertility Drugs Market by Drug Class
Chapter 7. Company Profiles
7.1 Abbott Laboratories
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.1.5 SWOT Analysis
7.2 Bayer AG
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent strategies and developments:
7.2.5.1 Partnerships, Collaborations, and Agreements:
7.2.5.2 Acquisition and Mergers:
7.3 Novartis AG
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expense
7.4 Merck & Co., Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expenses
7.5 Pfizer, Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional & Segmental Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Partnerships, Collaborations, and Agreements:
7.6 Teva Pharmaceutical Industries Ltd.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expenses
7.7 Sanofi S.A.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.8 Ferring Holdings SA
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research and Development Expense
7.8.5 Recent strategies and developments:
7.8.5.1 Partnerships, Collaborations, and Agreements:
7.9 Organon & Co.
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Regional Analysis
7.9.4 Research & Development Expenses
7.10. Mankind Pharma Ltd.
7.10.1 Company Overview
7.10.2 Recent strategies and developments:
7.10.2.1 Product Launches and Product Expansions:
Companies Mentioned
- Abbott Laboratories
- Bayer AG
- Novartis AG
- Merck & Co., Inc.
- Pfizer, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Sanofi S.A.
- Ferring Holdings SA
- Organon & Co.
- Mankind Pharma Ltd.
Methodology
LOADING...
